Autopsy report · NCT04897880

A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT

“Drug supply”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 years 4 months after it had already started.
• Ran for about 5 years 4 months before it stopped.
• 25 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Australian & New Zealand Children's Haematology/Oncology Group

Sponsor type

University, hospital or other

Conditions

Rhabdoid Tumor; Atypical Teratoid/Rhabdoid Tumor; Malignant Rhabdoid Tumor; Recurrent Brain Tumor, Childhood

Interventions

Panobinostat

Participants

25

Sites

11

Countries

Australia, New Zealand, United States

Trials that died the same way

• Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer
  “Drug supply issues” (83% match in meaning)
• Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies
  “Problem with drug supply” (79% match in meaning)
• rhEndostatin Protein Involving Pediatric Patients With Cancer
  “Lack of drug supply” (76% match in meaning)
• Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones
  “Insufficient drug supply” (74% match in meaning)
• MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma
  “insufficient suitable drug supply” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.